Evaluation of pentamidine tolerability and efficacy between CYP2C19 phenotypes.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-10-01 Epub Date: 2023-10-17 DOI:10.2217/pgs-2023-0093

Alexis Koon, Jiaxian He, Jai Patel, Allison Morse, Victoria Boseman, Alicia Hamilton, Thomas Knight, Nilay Shah, Brittany Ragon, Aleksander Chojecki, Jing Ai, Nury Steuerwald, Jonathan Gerber, Edward Copelan, Michael Grunwald, Justin Arnall

{"title":"Evaluation of pentamidine tolerability and efficacy between CYP2C19 phenotypes.","authors":"Alexis Koon, Jiaxian He, Jai Patel, Allison Morse, Victoria Boseman, Alicia Hamilton, Thomas Knight, Nilay Shah, Brittany Ragon, Aleksander Chojecki, Jing Ai, Nury Steuerwald, Jonathan Gerber, Edward Copelan, Michael Grunwald, Justin Arnall","doi":"10.2217/pgs-2023-0093","DOIUrl":null,"url":null,"abstract":"Intravenous pentamidine is used for prophylaxis against Pneumocystis jirovecii pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by CYP2C19, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as P. jirovecii pneumonia prophylaxis. The primary objective was the association between CYP2C19 phenotype and discontinuation of pentamidine due to drug-related side effects based on univariate logistic regression (N = 81). Ten patients (12.3%) discontinued pentamidine because of side effects. There was no difference in discontinuation between phenotype groups (p = 0.18) or discontinuation due to side effects (p = 0.76). Overall, no association was seen between phenotypes and pentamidine-related side effects (p = 0.475). Drug discontinuation rates and P. jirovecii pneumonia infection rates were low.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0093","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Intravenous pentamidine is used for prophylaxis against Pneumocystis jirovecii pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by CYP2C19, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as P. jirovecii pneumonia prophylaxis. The primary objective was the association between CYP2C19 phenotype and discontinuation of pentamidine due to drug-related side effects based on univariate logistic regression (N = 81). Ten patients (12.3%) discontinued pentamidine because of side effects. There was no difference in discontinuation between phenotype groups (p = 0.18) or discontinuation due to side effects (p = 0.76). Overall, no association was seen between phenotypes and pentamidine-related side effects (p = 0.475). Drug discontinuation rates and P. jirovecii pneumonia infection rates were low.

查看原文本刊更多论文

CYP2C19表型间戊脒耐受性和疗效的评估。

静脉注射戊脒用于预防吉氏肺孢子虫肺炎，这是一种在造血干细胞移植受者中发现的感染。戊脒被CYP2C19部分代谢，CYP2C19易受药物遗传变异的影响。这项回顾性研究评估了异基因造血干细胞移植患者接受静脉注射戊脒作为吉氏疟原虫肺炎预防药物。主要目的是基于单变量逻辑回归的CYP2C19表型与因药物相关副作用而停用戊脒之间的相关性（N=81）。10名患者（12.3%）因副作用停用了戊脒。表型组之间的停药（p=0.18）或因副作用而停药（p=0.76）没有差异。总体而言，表型与戊脒相关副作用之间没有关联（p=0.475）。停药率和吉氏疟原虫肺炎感染率较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.